Waltz Quoted on Payment Reporting for Drug & Device Makers

Partner Judy Waltz was quoted in a Bloomberg BNA article, “Drug, Device Markers Could Get Hit for Not Reporting Payments to Doctors,” covering the current and future states of the Open Payments program.

Waltz explained that Open Payments reporting “remains an administrative burden for drug and device manufacturers” but “payment reporting is becoming widespread throughout the health-care industry.” She also explained, as it relates to the future of the program, “the Trump administration has spoken about reducing regulatory burdens, and Open Payments could fit under that category.”